Exelixis (EXEL) News Today → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free EXEL Stock Alerts $20.91 -0.32 (-1.51%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 6:43 AM | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Director Sells $233,424.51 in StockMay 17 at 5:52 PM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Short Interest Up 11.0% in AprilExelixis, Inc. (NASDAQ:EXEL - Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 9,570,000 shares, a growth of 11.0% from the April 15th total of 8,620,000 shares. Currently, 3.4% of the company's shares are short sold. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is presently 4.0 days.May 17 at 6:45 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Bought by BNP Paribas Financial MarketsBNP Paribas Financial Markets increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 88.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 450,097 shares of the biotechnology company'May 16 at 1:19 PM | insidertrades.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells 10,923 Shares of StockMay 16 at 5:18 AM | americanbankingnews.comExelixis (NASDAQ:EXEL) Coverage Initiated at StephensMay 15, 2024 | msn.comStephens & Co. Initiates Coverage of Exelixis (EXEL) with Equal-Weight RecommendationMay 14, 2024 | stocknews.com3 A-Rated Biotech Stocks for Long-Term InvestorsMay 14, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Now Covered by Analysts at StephensStephens began coverage on shares of Exelixis in a report on Tuesday. They issued an "equal weight" rating and a $23.00 price target on the stock.May 12, 2024 | marketbeat.comSeizert Capital Partners LLC Sells 43,339 Shares of Exelixis, Inc. (NASDAQ:EXEL)Seizert Capital Partners LLC lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 420,335 shares of the biotMay 12, 2024 | fool.comBillionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?May 11, 2024 | msn.comExelixis files patent suit against India’s Cipla over Cabometyx genericsMay 11, 2024 | marketbeat.comSwiss National Bank Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)Swiss National Bank lessened its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 564,700 shares of the biotechnology company's stock after selling 79,500 shMay 10, 2024 | marketwatch.comExelixis Files Patent Complaint Against Cipla's Cancer TreatmentMay 9, 2024 | marketbeat.comLSV Asset Management Sells 879,211 Shares of Exelixis, Inc. (NASDAQ:EXEL)LSV Asset Management trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 84.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,429 shares of the biotechnology company's stock after selMay 7, 2024 | businesswire.comExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayMay 4, 2024 | marketbeat.comSummit Global Investments Purchases Shares of 38,458 Exelixis, Inc. (NASDAQ:EXEL)Summit Global Investments purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 38,458 shares of the biotechnology company's stock, valued at approximately $923May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exelixis Amid Solid Revenue and Strategic Growth InitiativesMay 3, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Exelixis (NASDAQ:EXEL)HC Wainwright reissued a "buy" rating and issued a $28.00 price objective on shares of Exelixis in a report on Friday.May 3, 2024 | marketbeat.comWilliam Blair Comments on Exelixis, Inc.'s Q3 2024 Earnings (NASDAQ:EXEL)Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at William Blair decreased their Q3 2024 EPS estimates for Exelixis in a research report issued on Wednesday, May 1st. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.27 per share for thMay 2, 2024 | markets.businessinsider.comHold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline ProgressMay 2, 2024 | seekingalpha.comExelixis: With Patent Litigation Decision Due Soon, There Are OptionsMay 2, 2024 | finance.yahoo.comExelixis, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 1, 2024 | finance.yahoo.comGiants of Cancer Care® Announces the 12th Annual Class of InducteesMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Exelixis (EXEL) and Merit Medical Systems (MMSI)May 1, 2024 | finance.yahoo.comExelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring EffortsMay 1, 2024 | markets.businessinsider.comThe Analyst Verdict: Exelixis In The Eyes Of 5 ExpertsMay 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Given New $27.00 Price Target at TD CowenTD Cowen boosted their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Announces Earnings ResultsExelixis (NASDAQ:EXEL - Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The company had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The business's revenue for the quarter was up 4.0% on a year-over-year basis.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Stock Rating Reaffirmed by William BlairWilliam Blair reissued an "outperform" rating on shares of Exelixis in a report on Wednesday.May 1, 2024 | marketbeat.comExelixis (NASDAQ:EXEL) Shares Gap Down on Disappointing EarningsExelixis (NASDAQ:EXEL) Shares Gap Down After Earnings MissMay 1, 2024 | msn.comExelixis down 7% as Q1 financial results disappointMay 1, 2024 | finance.yahoo.comExelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 1, 2024 | finance.yahoo.comQ1 2024 Exelixis Inc Earnings CallMay 1, 2024 | marketbeat.comRussell Investments Group Ltd. Purchases 37,438 Shares of Exelixis, Inc. (NASDAQ:EXEL)Russell Investments Group Ltd. raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,513,591 shares of the biotechnology companMay 1, 2024 | fool.comExelixis (EXEL) Q1 2024 Earnings Call TranscriptApril 30, 2024 | finance.yahoo.comExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateApril 29, 2024 | msn.comExelixis Q1 2024 Earnings PreviewApril 29, 2024 | markets.businessinsider.comHere's what Wall Street expects from Exelixis's earnings reportApril 28, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Sees Large Increase in Short InterestExelixis, Inc. (NASDAQ:EXEL - Get Free Report) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 8,620,000 shares, a growth of 26.2% from the March 31st total of 6,830,000 shares. Based on an average daily trading volume, of 2,240,000 shares, the short-interest ratio is presently 3.8 days. Currently, 3.0% of the company's stock are sold short.April 27, 2024 | investorplace.comThe Top 3 Biotech Stocks to Buy in April 2024April 27, 2024 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Holdings Raised by California Public Employees Retirement SystemCalifornia Public Employees Retirement System lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 11.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,974,291 shares of the biotechnology company's stock afterApril 26, 2024 | marketbeat.comBrokers Issue Forecasts for Exelixis, Inc.'s Q2 2024 Earnings (NASDAQ:EXEL)Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2024 earnings estimates for shares of Exelixis in a note issued to investors on Wednesday, April 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn $0.29April 25, 2024 | finance.yahoo.comExelixis, Inc. (EXEL)April 25, 2024 | marketbeat.comabrdn plc Invests $16 Million in Exelixis, Inc. (NASDAQ:EXEL)abrdn plc bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 666,837 shares of the biotechnology company's stock, valued at appApril 23, 2024 | finance.yahoo.comGlobal Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical DevelopmentsApril 23, 2024 | marketbeat.comExelixis (EXEL) to Release Earnings on TuesdayExelixis (NASDAQ:EXEL) will be releasing earnings after the market closes on Tuesday, April 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=585308)April 22, 2024 | marketbeat.com67,884 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Calamos Advisors LLCCalamos Advisors LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 67,884 shares of the biotechnology company's stock, valued atApril 18, 2024 | finance.yahoo.comGlobal Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90%April 18, 2024 | marketbeat.comLouisiana State Employees Retirement System Makes New $2.09 Million Investment in Exelixis, Inc. (NASDAQ:EXEL)Louisiana State Employees Retirement System purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 87,300 shares of the bioteApril 17, 2024 | finance.yahoo.comInstitutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. EXEL Media Mentions By Week EXEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.760.42▲Average Medical News Sentiment EXEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼107▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Halozyme Therapeutics News Repligen News National Research News Charles River Laboratories International News Medpace News Precigen News Luna Innovations News Neurocrine Biosciences News Revolution Medicines News ImmunityBio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchDems have chosen Biden replacement?Paradigm PressWhat’s Really Next for America…Porter & CompanyBreaking News: Elon Musk Invents New Type of A.I. (Shocking)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
